In this episode, we explore the groundbreaking results of the EMPA-KIDNEY trial, a large-scale clinical study that highlights the long-term benefits of Empagliflozin (SGLT2 inhibitor) in patients with chronic kidney disease (CKD). We dive into how the treatment slowed disease progression, reduced cardiovascular deaths, and provided lasting benefits even after the therapy ended. Join us as we break down the study’s key findings, discuss their real-world implications, and uncover what makes this treatment a game-changer for CKD management.
Podden och tillhörande omslagsbild på den här sidan tillhör
Mohammed Al-Qadami. Innehållet i podden är skapat av Mohammed Al-Qadami och inte av,
eller tillsammans med, Poddtoppen.
